Carfilzomib-lenalidomide-dexamethasone Vs. lenalidomide-dexamethasone in non-frail transplant-ineligible patients with newly diagnosed multiple myeloma: the EMN20 trial

被引：0

作者：

D'Agostino, Mattia ^{[1
,2
]}

Antonioli, Elisabetta ^{[3
]}

Gamberi, Barbara ^{[4
]}

Bruno, Benedetto ^{[1
,2
]}

Derudas, Daniele ^{[5
]}

Tosi, Patrizia ^{[6
]}

Fazio, Francesca ^{[7
]}

Carlo-Stella, Carmelo ^{[8
,9
]}

Ronconi, Sonia ^{[10
]}

Corradini, Paolo ^{[11
]}

Ballanti, Stelvio ^{[12
]}

Cellini, Claudia ^{[13
]}

Falcone, Antonietta Pia ^{[14
]}

Bringhen, Sara ^{[15
]}

Offidani, Massimo ^{[16
]}

Rambaldi, Alessandro ^{[17
]}

Rota-Scalabrini, Delia ^{[18
]}

Agazzi, Alberto ^{[19
]}

Casaluci, Gloria Margiotta ^{[20
]}

Pietrantuono, Giuseppe ^{[21
]}

Patriarca, Francesca ^{[22
,23
]}

Larocca, Alessandra ^{[2
,15
]}

Boccadoro, Mario ^{[24
]}

机构：

[1] Azienda Osped Univ Citta Salute & Sci Torino, Div Hematol, Turin, Italy

[2] Univ Torino, Div Hematol, Dept Mol Biotechnol & Hlth Sci, Turin, Italy

[3] AOU Careggi, UO Ematol, Florence, Italy

[4] Azienda USL IRCCS Reggio Emilia, Reggio Emilia, Italy

[5] ARNAS G Brozu, Osped Oncol Riferimento Reg A Businco, SC Ematol & CTMO, Cagliari, Italy

[6] Osped Rimini, UO Ematol, Rimini, Italy

[7] Sapienza Univ Rome, Dept Translat & Precis Med, Hematol, Rome, Italy

[8] Humanitas Clin & Res Ctr, Dept Oncol & Hematol, Humanitas Canc Ctr, Rozzano, Italy

[9] Humanitas Univ, Dept Biomed Sci, Rozzano, Italy

[10] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Meldola, Italy

[11] Fdn IRCCS Ist Nazl Tumori, Milan, MI, Italy

[12] Osped Santa Maria Misericordia, Sez Ematol & Immunol Clin, Localita St Andrea Fratte, Perugia, Italy

[13] Osped Santa Maria Croci, UOC Ematol, AUSL Romagna, Ravenna, Italy

[14] IRCCS Casa Sollievo della Sofferenza Hosp, Hematol, San Giovanni Rotondo, Italy

[15] Azienda Osped Univ Citta Salute & Sci Torino, Dept Oncol, SSD Clin Trial Oncoematol & Mieloma Multiplo, Turin, Italy

[16] Azienda Osped Univ Marche, Clin Ematol, Ancona, Italy

[17] ASST Papa Giovanni XXIII, UO Ematol, Bergamo, Italy

[18] FPO IRCCS, Candiolo Canc Inst, Dept Med Oncol, Turin, Italy

[19] European Inst Oncol, Hematoncol Div, Milan, Italy

[20] AOU Maggiore Carita, Novara, Italy

[21] IRCCS Ctr Riferimento Oncol Basilicata, Hematol & Stem Cell Transplantat Unit, Rionero In Vulture, Italy

[22] Univ Udine, Dipartimento Area Med DAME, ASUFC, Clin Ematol, Udine, Italy

[23] Univ Udine, Unita Terapie Cellulari, ASUFC, Clin Ematol, Udine, Italy

[24] European Myeloma Network, Milan, Italy

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-109

引用

页码：S94 / S95

页数：2

共 50 条

[41] Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma
Richardson, Paul G.
Hofmeister, Craig C.
Rosenbaum, Cara A.
Htut, Myo
Vesole, David H.
Berdeja, Jesus G.
Liedtke, Michaela
Chari, Ajai
Smith, Stephen D.
Lebovic, Daniel
Raje, Noopur
Byrne, Catriona
Liao, Eileen
Gupta, Neeraj
Di Bacco, Alessandra
Estevam, Jose
Berg, Deborah
Baz, Rachid
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (02) : 231 - 244
[42] Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma
Usmani, S. Z.
Cavenagh, J. D.
Belch, A. R.
Hulin, C.
Basu, S.
White, D.
Nooka, A.
Ervin-Haynes, A.
Yiu, W.
Nagarwala, Y.
Berger, A.
Pelligra, C. G.
Guo, S.
Binder, G.
Gibson, C. J.
Facon, T.
JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (03) : 243 - 258
[43] Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
Gay, Francesca
Musto, Pellegrino
Rota-Scalabrini, Delia
Bertamini, Luca
Belotti, Angelo
Galli, Monica
Offidani, Massimo
Zamagni, Elena
Ledda, Antonio
Grasso, Mariella
Ballanti, Stelvio
Spadano, Antonio
Cea, Michele
Patriarca, Francesca
D'Agostino, Mattia
Capra, Andrea
Giuliani, Nicola
de Fabritiis, Paolo
Aquino, Sara
Palmas, Angelo
Gamberi, Barbara
Zambello, Renato
Petrucci, Maria Teresa
Corradini, Paolo
Cavo, Michele
Boccadoro, Mario
LANCET ONCOLOGY, 2021, 22 (12): : 1705 - 1720
[44] Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
Derman, Benjamin A.
Cooperrider, Jennifer
Rosenblatt, Jacalyn
Avigan, David E.
Rampurwala, Murtuza
Barnidge, David
Major, Ajay
Karrison, Theodore
Jiang, Ken
Ramsland, Aubrianna
Kubicki, Tadeusz
Jakubowiak, Andrzej J.
BLOOD CANCER JOURNAL, 2024, 14 (01):
[45] Comparative Efficacy of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Vs. Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRD) in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis
Wang, Yuqi
Huan, Chen
Hanzhen, Zhang
Zhang, Shanshan
Yuan, Youhai
Feng, Ru
Wei, Yongqiang
Wei, Xiaolei
BLOOD, 2024, 144 : 7031 - 7031
[46] A Randomized Study of Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Cyclophosphamide-Dexamethasone Induction in Newly Diagnosed Myeloma Patients Eligible for Transplant: High Efficacy in High- and Standard- Risk Patients
Gay, Francesca Maria
Scalabrini, Delia Rota
Belotti, Angelo
Galli, Monica
Zamagni, Elena
Offidani, Massimo
Oliva, Stefania
Montefusco, Vittorio
Zambello, Renato
Ledda, Antonio
Grasso, Mariella
Aquino, Sara
Esma, Fabrizio
Tosi, Patrizia
Pisani, Francesco
Annibali, Ombretta
Liberati, Anna Marina
Baraldi, Anna
Galieni, Piero
Specchia, Giorgina
Pescosta, Norbert
Mancuso, Katia
Paris, Laura
Ribolla, Rossella
Coha, Valentina
Palumbo, Antonio
Musto, Pellegrino
Cavo, Michele
Boccadoro, Mario
BLOOD, 2017, 130
[47] Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone
Vogl, Dan T.
Delforge, Michel
Song, Kevin
Guo, Shien
Gibson, Craig J.
Ervin-Haynese, Annette
Facon, Thierry
LEUKEMIA & LYMPHOMA, 2018, 59 (02) : 398 - 405
[48] Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma
Dytfeld, Dominik
Jasielec, Jagoda
Griffith, Kent A.
Lebovic, Daniel
Vesole, David H.
Jagannath, Sundar
Al-Zoubi, Ammar
Anderson, Tara
Detweiler-Short, Kristen
Stockerl-Goldstein, Keith
Ahmed, Asra
Jobkar, Terri
Durecki, Diane E.
McDonnell, Kathryn
Mietzel, Melissa
Couriel, Daniel
Kaminski, Mark
Vij, Ravi
Jakubowiak, Andrzej J.
HAEMATOLOGICA, 2014, 99 (09) : E162 - E164
[49] Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I/II study
Terpos, Evangelos
Gavriatopoulou, Maria
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vasiliki
Kostopoulos, Ioannis V.
Syrigou, Rodanthi-Eleni
Eleutherakis-Papaiakovou, Evangelos
Gkolfinopoulos, Stavros
Tsitsilonis, Ourania E.
Kastritis, Efstathios
Dimopoulos, Meletios A.
HAEMATOLOGICA, 2024, 109 (08) : 2594 - 2605
[50] Isatuximab, Plus Bortezomib, Lenalidomide, and Dexamethasone (VRd) for Newly Diagnosed Multiple Myeloma (NDMM) Transplant-ineligible Patients: Frailty Subgroup Analysis of IMROZ
Manier, Salomon
Dimopoulos, Meletios-Athanasios
Leleu, Xavier
Moreau, Philippe
Cavo, Michele
Goldschmidt, Hartmut
Orlowski, Robert Z.
Tron, Muriel
Tekle, Christina
Bregeault, Marie-France
Shafer, Andrea
Beksac, Meral
Facon, Thierry
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S290 - S291

← 1 2 3 4 5 →